News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Petra Vuković

Articles by Petra Vuković

17 TROPION-Breast05: A Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Chemotherapy (CT) Plus Pembrolizumab in Patients (pts) With PD-L1–Positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC)

17 TROPION-Breast05: A Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Chemotherapy (CT) Plus Pembrolizumab in Patients (pts) With PD-L1–Positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC)

ByStephanie L. Graff, MD,Peter Schmid, MD,Massimo Cristofanilli, MD,David W. Cescon,Tina Hovey,Karson Tse,Petra Vuković,Joyce O’Shaughnessy, MD

August 11th 2024

4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study

ByJamil Asselah,Cynthia X. Ma, MD, PhD,Zbigniew Nowecki,Robert Huisden,Ross Stewart,Petra Vuković,Peter Schmid, MD

April 28th 2023

Latest Updated Articles

Trending on CancerNetwork

Nab-Sirolimus Regimens Show Promise in HR+/HER2-Negative Breast Cancer

FDA Approves Narsoplimab for HSCT-Associated Thrombotic Microangiopathy

Ivosidenib Combo Shows Preliminary Activity in IDH1-Mutated AML

‘Seamlessly’ Integrating Bioimpedance Spectroscopy Into Clinical Workflows

Bioimpedance Spectroscopy is Allowing for Lymphedema Reduction in Breast Cancer